Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
MimiVax, Inc. logo — Disrupting Cancer with Immunotherapy

MimiVax, Inc.

Disrupting Cancer with Immunotherapy

Founded 2012 United States Buffalo, United States 3 employees Venture round Total: $16.55M Biopharma, Biotechnology +1

General Information

Company Name MimiVax, Inc.
Founded Year 2012
Location United States Buffalo, United States
Founders / Decision Makers
Team member
Employees 3
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with MimiVax, Inc.. To contact MimiVax, Inc., visit mimivax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MimiVax, Inc. compare?

A PDF of MimiVax, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MimiVax, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MimiVax, Inc.

MimiVax, Inc. is a privately held, clinical-stage biotechnology company founded in 2012 with a vision to disrupt cancer through highly innovative immunotherapies. The company's lead immunotherapeutic vaccine, , has shown promise by completing a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. Furthermore, MimiVax is actively pursuing additional indications through Phase 1 clinical trials in multiple myeloma in combination with REVLIMID® (lenalidomide), Phase 1 in Neuro-Endocrine Tumors (NET), and a Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma, and DIPG. The recent Venture Round investment on 09 January 2024 has brought in new support from prominent investors such as Meda Angels, Varia Ventures, Brain Tumor Investment Fund, Sontag Family Trust. MimiVax's commitment to revolutionizing cancer treatment through immunotherapy presents a compelling opportunity for potential investors in the biopharma, biotechnology, and pharmaceutical sectors.

Business keywords: Immunotherapy, Cancer treatment, Clinical-stage company, Immunotherapeutic vaccines, Targeted therapies, Survivin-targeting technology, Glioblastoma, Multiple myeloma, Neuro-Endocrine Tumors, Pediatric High Grade Glioma, Medulloblastoma, DIPG, Oncology, Pharmaceutical development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 4
Meda Angels Varia Ventures Brain Tumor Investment Fund
Meda Angels, Varia Ventures +2
09 Jan 2024
Series B $5.00M -
10 Dec 2021
Non Equity Assistance $10.00M -
12 Nov 2019
Venture Round $1.55M -
25 Aug 2015

MimiVax, Inc. Alternatives & Competitors

View All Alternatives
MimiVax, Inc. vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
MimiVax, Inc. vs
Imvax, Inc.
Imvax, Inc. United States

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunot...

24 employees
Biotechnology, Health and Wellness
MimiVax, Inc. vs
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. United States

A late-stage clinical biopharmaceutical company focused on developing novel therapies for a range of...

Post-IPO Equity
18 employees
Biopharma, Biotechnology
View all alternatives

FAQ About MimiVax, Inc.

Disrupting Cancer with Immunotherapy
MimiVax, Inc. was founded in 2012.
MimiVax, Inc. is headquartered in Buffalo, United States.
MimiVax, Inc. operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Immunotherapy, Cancer treatment, Clinical-stage company and Immunotherapeutic vaccines.
MimiVax, Inc. has approximately 3 employees.
MimiVax, Inc. has completed 4 funding rounds, raising a total of $16.55M. The latest funding stage is Venture round.
Top alternatives and competitors to MimiVax, Inc. include Prescient Therapeutics, Imvax, Inc., SELLAS Life Sciences Group, Inc., NexImmune, Inc., Lisata Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MimiVax, Inc. and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MimiVax, Inc., https://bouncewatch.com/company/mimivax-inc, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout